{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:41:35Z","timestamp":1791909695293,"version":"4.3.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with immunocompromising conditions are at increased risk for coronavirus disease 2019 (COVID-19)\u2013related hospitalizations and deaths. Randomized clinical trials provide limited enrollment, if any, to provide information on the outcomes in such patients treated with remdesivir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the US PINC AI Healthcare Database, we identified adult patients with immunocompromising conditions, hospitalized for COVID-19 between December 2021 and February 2024. The primary outcome was all-cause inpatient mortality examined in propensity score\u2013matched patients in remdesivir vs nonremdesivir groups. Subgroup analyses were performed for patients with cancer, hematological malignancies, and solid organ or hematopoietic stem cell transplant recipients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 28 966 patients included in the study, 16 730 (58%) received remdesivir during the first 2 days of hospitalization. After propensity score matching, 8822 patients in the remdesivir and 8822 patients in the nonremdesivir group were analyzed. Remdesivir was associated with a significantly lower mortality rate among patients with no supplemental oxygen (adjusted hazard ratio [95% confidence interval], 0.73 [.62\u2013.86] at 14 days and 0.79 [.68\u2013.91] at 28 days) and among those with supplemental oxygen (0.75 [.67\u2013.85] and 0.78 [.70\u2013.86], respectively). Remdesivir was also associated with lower mortality rates in subgroups of patients with cancer, hematological malignancies (leukemia, lymphoma, or multiple myeloma), and solid organ or hematopoietic stem cell transplants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this large cohort of patients with immunocompromising conditions hospitalized for COVID-19, remdesivir was associated with significant improvement in survival, including patients with varied underlying immunocompromising conditions. The integration of current real-world evidence into clinical guideline recommendations can inform clinical communities to optimize treatment decisions in the evolving COVID-19 era, extending beyond the conclusion of the public health emergency declaration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae510","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:05:08Z","timestamp":1729019108000},"page":"S149-S159","source":"Crossref","is-referenced-by-count":19,"title":["Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era"],"prefix":"10.1093","volume":"79","author":[{"given":"Essy","family":"Mozaffari","sequence":"first","affiliation":[{"name":"Medical Affairs, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-435X","authenticated-orcid":false,"given":"Aastha","family":"Chandak","sequence":"additional","affiliation":[{"name":"Evidence and Access, Certara , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-8709","authenticated-orcid":false,"given":"Robert L","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor University Medical Center , Dallas, Texas ,","place":["USA"]},{"name":"Baylor Scott & White Heart and Vascular Hospital , Dallas, Texas ,","place":["USA"]},{"name":"Baylor Scott & White The Heart Hospital , Plano, Texas ,","place":["USA"]},{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0730-9871","authenticated-orcid":false,"given":"Chidinma","family":"Chima-Melton","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Tele-ICU , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-2012","authenticated-orcid":false,"given":"Mark","family":"Berry","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9790-0245","authenticated-orcid":false,"given":"Alpesh N","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of California Irvine , Irvine, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-174X","authenticated-orcid":false,"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6489-6294","authenticated-orcid":false,"given":"Andre C","family":"Kalil","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"2024121311263217400_ciae510-B1","doi-asserted-by":"crossref","first-page":"e1259","DOI":"10.1002\/iid3.1259","article-title":"Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review","volume":"12","author":"Bytyci","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2024121311263217400_ciae510-B2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"key":"2024121311263217400_ciae510-B3","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.trre.2021.100628","article-title":"The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis","volume":"35","author":"Ao","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"2024121311263217400_ciae510-B4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1097\/QAD.0000000000002968","article-title":"An updated meta-analysis on the association between HIV infection and COVID-19 mortality","volume":"35","author":"Wang","year":"2021","journal-title":"AIDS"},{"key":"2024121311263217400_ciae510-B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2024121311263217400_ciae510-B6","first-page":"100461","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada","volume":"20","author":"Bahremand","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2024121311263217400_ciae510-B7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2024121311263217400_ciae510-B8","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024121311263217400_ciae510-B9","author":"COVID-19 Treatment Guidelines Panel"},{"key":"2024121311263217400_ciae510-B10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3348\/kjr.2023.0992","article-title":"Clinical and imaging characteristics of SARS-CoV-2 breakthrough infection in hospitalized immunocompromised patients","volume":"25","author":"Lee","year":"2024","journal-title":"Korean J Radiol"},{"key":"2024121311263217400_ciae510-B11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.cmi.2022.02.039","article-title":"Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis","volume":"28","author":"Gatti","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024121311263217400_ciae510-B12","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2024121311263217400_ciae510-B13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"key":"2024121311263217400_ciae510-B14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jinf.2023.01.024","article-title":"Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study","volume":"86","author":"Kang","year":"2023","journal-title":"J Infect"},{"key":"2024121311263217400_ciae510-B15","doi-asserted-by":"crossref","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024121311263217400_ciae510-B16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121311263217400_ciae510-B17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13665-024-00338-z","article-title":"Management of SARS-CoV-2 and persistent viral detection in solid organ transplant recipients","volume":"13","author":"Castro","year":"2024","journal-title":"Curr Pulmonol Rep"},{"key":"2024121311263217400_ciae510-B18","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciaa478","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19","volume":"78","author":"Bhimraj","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2024121311263217400_ciae510-B19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2021.11.007","article-title":"ESCMID COVID-19 living guidelines: drug treatment and clinical management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024121311263217400_ciae510-B20","doi-asserted-by":"crossref","first-page":"2100048","DOI":"10.1183\/13993003.00048-2021","article-title":"Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline","volume":"57","author":"Chalmers","year":"2021","journal-title":"Eur Respir J"},{"key":"2024121311263217400_ciae510-B21","author":"World Health Organization"},{"key":"2024121311263217400_ciae510-B22"},{"key":"2024121311263217400_ciae510-B23","doi-asserted-by":"crossref","first-page":"e14301","DOI":"10.1111\/tid.14301","article-title":"Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review","volume":"26","author":"Kinsella","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"2024121311263217400_ciae510-B24","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/cid\/ciae308","article-title":"How immunocompromised hosts were left behind in the quest to control the COVID-19 pandemic","volume":"79","author":"Boeckh","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2024121311263217400_ciae510-B25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024121311263217400_ciae510-B26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024121311263217400_ciae510-B27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15585\/mmwr.mm7106a4","article-title":"Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants\u2014United States, June 2021\u2013January 2022","volume":"71","author":"Lambrou","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024121311263217400_ciae510-B28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7224a2","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron lineages\u2014United States, January 2022\u2013May 2023","volume":"72","author":"Ma","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024121311263217400_ciae510-B29","author":"US Department of Health and Human Services"},{"key":"2024121311263217400_ciae510-B30","doi-asserted-by":"crossref","first-page":"ofad482","DOI":"10.1093\/ofid\/ofad482","article-title":"Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants","volume":"10","author":"Mozaffari","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024121311263217400_ciae510-B31","doi-asserted-by":"crossref","first-page":"ofae202","DOI":"10.1093\/ofid\/ofae202","article-title":"Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen","volume":"11","author":"Mozaffari","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024121311263217400_ciae510-B32","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024121311263217400_ciae510-B33","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1093\/cid\/ciae512","article-title":"Management of vulnerable patients hospitalized for Coronavirus Disease 2019 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infec Dis"},{"key":"2024121311263217400_ciae510-B34","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/jac\/dkac253","article-title":"Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19","volume":"77","author":"Lafont","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024121311263217400_ciae510-B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000529788","article-title":"High in-hospital mortality in SARS-CoV-2-infected patients with active cancer disease during Omicron phase of the pandemic: insights from the CORONA Germany study","volume":"46","author":"Konermann","year":"2023","journal-title":"Oncol Res Treat"},{"key":"2024121311263217400_ciae510-B36","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/j.clon.2020.11.006","article-title":"Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis","volume":"33","author":"Zarifkar","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2024121311263217400_ciae510-B37","doi-asserted-by":"crossref","first-page":"e81127","DOI":"10.7554\/eLife.81127","article-title":"International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship","volume":"12","author":"Raad","year":"2023","journal-title":"Elife"},{"key":"2024121311263217400_ciae510-B38","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/cancers14194720","article-title":"Remdesivir decreases mortality in COVID-19 patients with active malignancy","volume":"14","author":"Jaroszewicz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024121311263217400_ciae510-B39","doi-asserted-by":"crossref","first-page":"100499","DOI":"10.1016\/j.esmoop.2022.100499","article-title":"COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)","volume":"7","author":"Castelo-Branco","year":"2022","journal-title":"ESMO Open"},{"key":"2024121311263217400_ciae510-B40","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10238-023-01004-5","article-title":"Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis","volume":"23","author":"Hardy","year":"2023","journal-title":"Clin Exp Med"},{"key":"2024121311263217400_ciae510-B41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2022.11.030","article-title":"AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants","volume":"181","author":"Giesen","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024121311263217400_ciae510-B42","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","article-title":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","volume":"37","author":"Cesaro","year":"2023","journal-title":"Leukemia"},{"key":"2024121311263217400_ciae510-B43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"2024121311263217400_ciae510-B44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"2024121311263217400_ciae510-B45","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.ekir.2021.06.023","article-title":"Use and safety of remdesivir in kidney transplant recipients with COVID-19","volume":"6","author":"Buxeda","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024121311263217400_ciae510-B46","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.transproceed.2022.10.043","article-title":"Remdesivir in solid organ recipients for COVID-19 pneumonia","volume":"54","author":"Fesu","year":"2022","journal-title":"Transplant Proc"},{"key":"2024121311263217400_ciae510-B47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12985-021-01700-2","article-title":"Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?","volume":"18","author":"Shafiekhani","year":"2021","journal-title":"Virol J"},{"key":"2024121311263217400_ciae510-B48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijid.2022.03.015","article-title":"COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome\u2014a retrospective cohort study","volume":"118","author":"Elec","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2024121311263217400_ciae510-B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-023-00900-3","article-title":"Remdesivir for the treatment of COVID-19: a narrative review","volume":"13","author":"Godwin","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2024121311263217400_ciae510-B50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1208\/s12248-023-00832-3","article-title":"Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir","volume":"25","author":"Gerhart","year":"2023","journal-title":"AAPS J"},{"key":"2024121311263217400_ciae510-B51","author":"American Society of Transplantation"},{"key":"2024121311263217400_ciae510-B52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/imj.16064","article-title":"Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia","volume":"53","author":"Moso","year":"2023","journal-title":"Intern Med J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae510\/59764759\/ciae510.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/Supplement_4\/S149\/61130393\/ciae510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/Supplement_4\/S149\/61130393\/ciae510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T11:33:14Z","timestamp":1734089594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/Supplement_4\/S149\/7823126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":52,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2024,12,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae510","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,10,15]]}}}